Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Intervention Feasibility	Immediately post-intervention	Feasibility will be evaluated by tracking the percentage of participants screened and enrolled.
Primary	Intervention Feasibility	Immediately post-intervention	Feasibility will be evaluated by tracking the average number of participants enrolled monthly.
Primary	Intervention Feasibility	Immediately post-intervention	Protocol adherence will be evaluated by recording the average number of modules completed by participants.
Primary	Intervention Acceptability	Immediately post-intervention	Acceptability will be evaluated with semi-structured interview questions to understand the participant's perception of MTI delivery and content and the perceived impact.
Secondary	Mean Change from Baseline in Anxiety Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anxiety Short-Form 8a will be used. The minimum score is 8, and the maximum score is 40. Higher scores indicate more anxiety.
Secondary	Mean Change from Baseline in Depression Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short-Form 8a will be used. The minimum score is 8, and the maximum score is 40. Higher scores indicate higher levels of depressive symptoms.
Secondary	Mean Change from Baseline in Stress Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Perceived Stress Scale will be used. The minimum score is 0, and the maximum score is 40. Higher scores indicate more perceived stress.
Secondary	Mean Change from Baseline in Self-Efficacy Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Chronic Disease Self-Efficacy Scale will be used. The minimum score is 6, and the maximum score is 60. Higher scores indicate more self-efficacy.
Secondary	Mean Change from Baseline in Quality of Life Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Multiple Sclerosis Quality of Life Questionnaire will be used. The minimum score is 27, and the maximum score is 135. Higher scores indicate worse quality of life.
Secondary	Mean Change from Baseline in Sleep Disturbance Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep disturbance Short-Form 6a will be used. The minimum score is 6, and the maximum score is 30. Higher scores indicate more sleep disturbance.
Secondary	Mean Change from Baseline in Attention Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Trail Making A\&B will be used to measure attention. Trails A and B are two separate timed tests. Faster time means greater attention.
Secondary	Mean Change from Baseline in Memory Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	Immediate and delayed recognition tests will be used. Participant are shown 10 words to memorize. In the immediate recognition test, they are immediately asked to identify the 10 words they memorized out of a list of 20. Later in the testing series, participants will again be asked to recall the 10 words. The number of correct responses will be scored. Higher scores means better memory.
Secondary	Mean Change from Baseline in Executive Functioning Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Digit-Symbol Substitution will be used to measure processing speed and accuracy to evaluate executive functioning. In this test, participants match arbitrary symbols to digits. Scores are calculated by the number of trials correctly completed in 60 seconds.
Secondary	Mean Change from Baseline in Executive Functioning Scores at 12 weeks and 16 weeks	Immediately post-intervention and 1-month post-intervention	The Stroop Color and Word Test evaluates impulse control and inhibition to evaluate executive functioning. When the name of a color (e.g., "blue," "green," or "red") is displayed in an incongruent color, name (for example, the word "blue" printed in red), naming the color of the word takes longer and is more prone to errors than when the word and color are congruent or neutral. The scoring uses median duration of incongruent trials.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05792176/registered

API reference For AI assistants